Get started
Author

November H. McGarvey

Observed names: McGarvey, November, N McGarvey, N. McGarvey, November McGarvey
ORCID: 0000-0003-4439-4788
Observed ORCID: 0000-0003-4439-4788
OpenAlex ID: A5083983885
Increased healthcare costs by later stage cancer diagnosis
2022 · November McGarvey, Matthew Gitlin, et al. · BMC Health Services Research · 107
PDF
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial
2021 · Jeremy S. Abramson, Tanya Siddiqi, et al. · Blood Advances · 36
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
2022 · Michael J. Germain, Subir K. Paul, et al. · BMC Nephrology · 15
PDF
Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy
2022 · Christopher E. Dandoy, Wan H. Tsong, et al. · Transplantation and Cellular Therapy · 14
Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol
2021 · George Fadda, Michael J. Germain, et al. · American Journal of Nephrology · 14
Food security among California's low-income adults improves, but most severely affected do not share in improvement.
2007 · Gail G Harrison, Matthew Sharp, et al. · PubMed · 14
PDF
Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States
2023 · November McGarvey, Matthew Gitlin, et al. · Journal of Medical Economics · 13
PDF
Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020
2022 · Ashley Kim, Matthew Gitlin, et al. · Preventive Medicine Reports · 13
PDF
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials
2021 · M. Lia Palomba, Monika Parisi Jun, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis
2023 · Matthew Gitlin, November McGarvey, et al. · Journal of Managed Care & Specialty Pharmacy · 11
PDF
Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa.
2020 · Parameswaran Hari, Andy Nguyen, et al. · Journal of Clinical Oncology · 10
Hemoglobin Decline in Chemotherapy Patients Prior to and after Policy Changes Affecting Use of Erythropoiesis-Stimulating Agents: 2006 – 2009
2012 · Jw Hill, Z Cong, et al. · Journal of International Medical Research · 6
More than 2.9 million Californians now food insecure--one in three low-income, an increase in just two years.
2005 · Gail G Harrison, George Manolo-LeClair, et al. · PubMed · 5
PDF
Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
2020 · M. Lia Palomba, Monika P. Jun, et al. · Blood · 3
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
2023 · November McGarvey, Brian Ung, et al. · Advances in Therapy · 2
PDF
PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
2021 · P. Hari, A. Nguyen, et al. · Value in Health · 2
Reductions in cancer screening: The consequence of changes in routine care during the COVID-19 pandemic.
2021 · Ashley Kim, Matthew Gitlin, et al. · Journal of Clinical Oncology · 2
P0901real-world Assessment: Clinical Effectiveness and Safety of Vitamin D Therapies in Nd-ckd Patients
2020 · Michael J Germain, Subir K Paul, et al. · Nephrology Dialysis Transplantation · 2
PDF
Understanding the Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
2025 · Briana M. Choi, Tavneet Singh, et al. · The Journal of Clinical Psychiatry · 1
Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase‐5 Inhibitors (PDE5i)
2025 · Nicholas A. Kolaitis, Martha Kingman, et al. · Pulmonary Circulation · 1
PDF
Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials
2023 · November McGarvey, Matthew Gitlin, et al. · Blood · 1
PDF
Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study
2023 · Ashley C. Saunders, Tavneet Singh, et al. · Blood · 1
Factors in nephrologists’ decision to treat pre-dialysis CKD patients with vitamin D insufficiency and SHPT: A discrete choice experiment
2023 · Anand C. Reddy, Andy Nguyen, et al. · PLoS ONE · 1
EE145 Increasing Out-of-Pocket Costs By Stage Among Commercially Insured Patients Diagnosed with Cancer 2016-2020
2022 · N McGarvey, M Gitlin, et al. · Value in Health · 1
EE286 Post-Infusion Monitoring Costs By Site of Care Among Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Who Received Second-LINE Treatment with Lisocabtagene Maraleucel (LISO-CEL) in the Transform Study: A United States Subgroup Analysis
2022 · N McGarvey, N Vaidya, et al. · Value in Health · 1
PDF
Works count: 50
Citation count: 289
H-index: 10
I10-index: 11
Year
Topic
Type